ATM、CHEK2和PALB2致病性变异女性的乳腺癌筛查策略:比较模型分析
该比较模型分析基于两个CISNET微模拟模型,评估ATM、CHEK2和PALB2致病性变异女性从不同年龄开始年度乳腺X线摄影和MRI筛查的获益与危害。结果显示,从30-35岁开始年度MRI并于40岁起联合乳腺X线摄影,预计可将乳腺癌死亡率降低超过50%;在MRI筛查背景下,40岁前加做乳腺X线摄影额外获益甚微。
要点
- ATM、CHEK2、PALB2变异女性终生乳腺癌风险模型均值分别为20.9%、27.6%、39.5%。
- 40-74岁单纯年度乳腺X线摄影较不筛查降低乳腺癌死亡率36.4%-38.5%。
- 30-35岁起年度MRI、40岁起联合乳腺X线摄影可降低死亡率54.4%-59.5%。
核心结论
- 分析提示,对ATM、CHEK2和PALB2致病性变异女性,从30-35岁开始年度MRI并于40岁起联合年度乳腺X线摄影,可能使乳腺癌死亡率降低超过50%。
- 在MRI筛查背景下,40岁前加做乳腺X线摄影可能额外获益甚微。
研究设计与样本
- 比较模型分析,使用癌症干预与监测建模网络(CISNET)的两个已建立乳腺癌微模拟模型评估不同筛查策略。
- 年龄别乳腺癌风险使用癌症风险估计与易感性联盟(CARRIERS)12项人群研究32 247例病例和32 544例对照的汇总数据估计。
- 乳腺X线摄影和MRI筛查性能数据来自已发表文献。
- 模型模拟1985年出生的美国ATM、CHEK2或PALB2致病性变异女性。
主要发现
- 模型估计的终生乳腺癌风险均值:ATM变异女性20.9%(18.1%-23.7%),CHEK2变异女性27.6%(23.4%-31.7%),PALB2变异女性39.5%(35.6%-43.3%)。
- 与不筛查相比,40-74岁单纯年度乳腺X线摄影预计降低乳腺癌死亡率36.4%(34.6%-38.2%)至38.5%(37.8%-39.2%)。
- 从35岁开始年度MRI并于40岁起联合年度乳腺X线摄影,预计降低死亡率54.4%(54.2%-54.7%)至57.6%(57.2%-58.0%),每1000名女性中假阳性筛查4661(4635-4688)至5001(4979-5023)次、良性活检1280(1272-1287)至1368(1362-1374)次。
- 从30岁开始年度MRI并于40岁起联合年度乳腺X线摄影,预计降低死亡率55.4%(55.3%-55.4%)至59.5%(58.5%-60.4%),每1000名女性中假阳性筛查5075(5057-5093)至5415(5393-5437)次、良性活检1439(1429-1449)至1528(1517-1538)次。
- 当30岁开始MRI时,30岁 vs 40岁开始年度乳腺X线摄影未显著降低平均死亡率(0.1%[0.1%-0.2%]至0.3%[0.2%-0.3%]),但每1000名女性预计增加假阳性筛查649(602-695)至650(603-696)次、良性活检58(41-76)至59(41-76)次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Screening mammography and magnetic resonance imaging (MRI) are recommended for women with ATM, CHEK2, and PALB2 pathogenic variants. However, there are few data to guide screening regimens for these women. OBJECTIVE: To estimate the benefits and harms of breast cancer screening strategies using mammography and MRI at various start ages for women with ATM, CHEK2, and PALB2 pathogenic variants. DESIGN, SETTING, AND PARTICIPANTS: This comparative modeling analysis used 2 established breast cancer microsimulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) to evaluate different screening strategies. Age-specific breast cancer risks were estimated using aggregated data from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium for 32 247 cases and 32 544 controls in 12 population-based studies. Data on screening performance for mammography and MRI were estimated from published literature. The models simulated US women with ATM, CHEK2, or PALB2 pathogenic variants born in 1985. INTERVENTIONS: Screening strategies with combinations of annual mammography alone and with MRI starting at age 25, 30, 35, or 40 years until age 74 years. MAIN OUTCOMES AND MEASURES: Estimated lifetime breast cancer mortality reduction, life-years gained, breast cancer deaths averted, total screening examinations, false-positive screenings, and benign biopsies per 1000 women screened. Results are reported as model mean values and ranges. RESULTS: The mean model-estimated lifetime breast cancer risk was 20.9% (18.1%-23.7%) for women with ATM pathogenic variants, 27.6% (23.4%-31.7%) for women with CHEK2 pathogenic variants, and 39.5% (35.6%-43.3%) for women with PALB2 pathogenic variants. Across pathogenic variants, annual mammography alone from 40 to 74 years was estimated to reduce breast cancer mortality by 36.4% (34.6%-38.2%) to 38.5% (37.8%-39.2%) compared with no screening. Screening with annual MRI starting at 35 years followed by annual mammography and MRI at 40 years was estimated to reduce breast cancer mortality by 54.4% (54.2%-54.7%) to 57.6% (57.2%-58.0%), with 4661 (4635-4688) to 5001 (4979-5023) false-positive screenings and 1280 (1272-1287) to 1368 (1362-1374) benign biopsies per 1000 women. Annual MRI starting at 30 years followed by mammography and MRI at 40 years was estimated to reduce mortality by 55.4% (55.3%-55.4%) to 59.5% (58.5%-60.4%), with 5075 (5057-5093) to 5415 (5393-5437) false-positive screenings and 1439 (1429-1449) to 1528 (1517-1538) benign biopsies per 1000 women. When starting MRI at 30 years, initiating annual mammography starting at 30 vs 40 years did not meaningfully reduce mean mortality rates (0.1% [0.1%-0.2%] to 0.3% [0.2%-0.3%]) but was estimated to add 649 (602-695) to 650 (603-696) false-positive screenings and 58 (41-76) to 59 (41-76) benign biopsies per 1000 women. CONCLUSIONS AND RELEVANCE: This analysis suggests that annual MRI screening starting at 30 to 35 years followed by annual MRI and mammography at 40 years may reduce breast cancer mortality by more than 50% for women with ATM, CHEK2, and PALB2 pathogenic variants. In the setting of MRI screening, mammography prior to 40 years may offer little additional benefit.
引用
- Lowry KP, Geuzinge HA, Stout NK, et al. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol. 2022. PMID: 35175286. doi:10.1001/jamaoncol.2021.6204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。